Cleared Traditional

K092399 - ANTI-MUTATED CITRULLINATED VIMENTIN EIA

K092399 is an FDA 510(k) clearance for ANTI-MUTATED CITRULLINATED VIMENTIN EIA, manufactured by Orgentec Diagnostika GmbH. The device is a Class 2 Immunology device with product code OQZ cleared through the Traditional 510(k) pathway after a 329-day FDA review.

K092399 · Orgentec Diagnostika GmbH · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2010
Decision
329d
Days
Class 2
Risk

K092399 is an FDA 510(k) clearance for the ANTI-MUTATED CITRULLINATED VIMENTIN EIA. Classified as Anti-mutated Citrullinated Vimentin Igg (product code OQZ), Class II - Special Controls.

Submitted by Orgentec Diagnostika GmbH (East Stroudsburg, US). The FDA issued a Cleared decision on July 1, 2010 after a review of 329 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5775 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Orgentec Diagnostika GmbH devices

FDA 510(k) Submission Details - K092399

510(k) Number K092399 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 06, 2009
Decision Date July 01, 2010
Days to Decision 329 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
224d slower than avg
Panel avg: 105d · This submission: 329d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

OQZ Device Classification - Class 2, Special Controls

Product Code OQZ Anti-mutated Citrullinated Vimentin Igg
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5775
Definition For The Semi-quantitative Measurement Of Igg Class Autoantibodies Against Mutated Citrullinated Vimentin (mcv) In Human Serum Or Plasma.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.